Trial · NCT07428369
Registered outcomes74
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
61 to 74 of 74
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Proportion with clinically meaningful improvement in GHS per EORTC QLQ-C30 | Up to 5 years | Phase 3 |
| Secondary | Proportion with clinically meaningful improvement in physical functioning per EORTC QLQ-C30 | Up to 5 years | Phase 3 |
| Secondary | Proportion with clinically meaningful improvement in role functioning per EORTC QLQ-C30 | Up to 5 years | Phase 3 |
| Secondary | Proportion with clinically meaningful improvement in pain per EORTC QLQ-C30 | Up to 5 years | Phase 3 |
| Secondary | Proportion with clinically meaningful improvement in fatigue per EORTC QLQ-C30 | Up to 5 years | Phase 3 |
| Secondary | Proportion with clinically meaningful improvement in disease symptoms per EORTC QLQ-MY20 | Up to 5 years | Phase 3 |
| Secondary | Proportion with clinically meaningful improvement in treatment side effects per EORTC QLQ-MY20 | Up to 5 years | Phase 3 |
| Secondary | Proportion with clinically meaningful improvement in body image per EORTC QLQ-MY20 | Up to 5 years | Phase 3 |
| Secondary | Proportion with clinically meaningful improvement in future perspective per EORTC QLQ-MY20 | Up to 5 years | Phase 3 |
| Secondary | Proportion of clinically meaningful improvement in EQ-5D-5L VAS | Up to 5 years | Phase 3 |
| Secondary | Mean proportion of time with high side effect bother as measured by Functional Assessment of Cancer Therapy (FACIT)- Item Global Population 5 (GP5) | Up to 5 years | Phase 3 FACIT-Item GP5 will be used to assess the patient-reported impact of treatment toxicity that uses a single item "I am bothered by side effects of treatment" on a 5-point scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much). |
| Secondary | Proportion of patients with high side effect bother as measured by FACIT- Item GP5 | Up to 5 years | Phase 3 |
| Secondary | Occurrence of Anti-Drug Antibody (ADA) to linvoseltamab in serum | Up to 5 years | Phase 3 |
| Secondary | Magnitude of ADA to linvoseltamab in serum | Up to 5 years | Phase 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07428369/registered?page=4